All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

• Published in: Annals of hematology Vol. 95; no. 12; pp. 1931 - 1942
• Main Authors: Schlenk, Richard F., Lübbert, Michael, Benner, Axel, Lamparter, Alexander, Krauter, Jürgen, Herr, Wolfgang, Martin, Hans, Salih, Helmut R., Kündgen, Andrea, Horst, Heinz-A., Brossart, Peter, Götze, Katharina, Nachbaur, David, Wattad, Mohammed, Köhne, Claus-Henning, Fiedler, Walter, Bentz, Martin, Wulf, Gerald, Held, Gerhard, Hertenstein, Bernd, Salwender, Hans, Gaidzik, Verena I, Schlegelberger, Brigitte, Weber, Daniela, Döhner, Konstanze, Ganser, Arnold, Döhner, Hartmut
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2016; Springer Nature B.V
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Female; Follow-Up Studies; Hematology; Humans; Induction Chemotherapy - methods; Induction Chemotherapy - mortality; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - mortality; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original; Original Article; Survival Rate - trends; Treatment Outcome; Tretinoin - administration & dosage; Young Adult; All; retinoic acid; Nucleophosmin-1; Acute myeloid leukemia; All-trans retinoic acid
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-016-2810-z

The aim of this clinical trial was to evaluate the impact of all- trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18–60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m 2 , days 6–8; 15 mg/m 2 , days 9–21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred patients were randomized (556, STANDARD; 544, ATRA) with 38 patients treated vice versa. Median follow-up for survival was 5.2 years. ITT analyses revealed no difference between ATRA and STANDARD for the total cohort and for the subset of NPM1 -mutated AML with respect to event-free (EFS; p  = 0.93, p  = 0.17) and overall survival (OS; p  = 0.24 and p  = 0.32, respectively). Pre-specified PP analyses revealed better EFS in NPM1 -mutated AML ( p  = 0.05) and better OS in the total cohort ( p  = 0.03). Explorative subgroup analyses on an ITT basis revealed better OS ( p  = 0.05) in ATRA for genetic low-risk patients according to ELN recommendations. The clinical trial is registered at clinicaltrialsregister.eu (EudraCT Number: 2004-004321-95).